CD86 and neoplasm: Phagocyte activation not only promotes tumor-associated antigen presentation and upregulates costimulatory B7 family molecules such as CD80/CD86 [4, 5] to trigger anti-tumor lymphocyte activation, but also initiates counter-regulatory signals that attenuate activation.